MGRX — MANGOCEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1938046 ·
Last close
$0.16
Market Cap
$3.45M
52W High
$1.38
52W Low
$0.15
ADV30
711,902
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 69,503 | 38,397 | -3,592,716 | -3,553,512 | 15,107,170 | 659,258 | 1,414,068 |
| Jun 2026 | 68,757 | 44,215 | -1,033,040 | -1,312,653 | 14,172,795 | 228,688 | 1,648,969 |
| Mar 2026 | 67,864 | 29,001 | -3,126,326 | -3,403,150 | 14,449,223 | 174,562 | 974,571 |
| Dec 2025 | 94,360 | 47,475 | -1,490,378 | -2,769,567 | 16,089,573 | 1,486,338 | 890,568 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,890,874
Investing CF
$0
Financing CF
$4,022,014
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.57
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-45,363,283
Inventory
$0
Receivables
$0
ST Investments
—
EBIT TTM
$-14,451,999
Pretax Income TTM
$-15,104,218
Interest Exp TTM
$652,219
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$315,227
EBITDA
$-12,097,073
Free Cash Flow
$1,268,902
Enterprise Value
$8,735,857
Total Cash
$228,688
Total Debt
$279,207
Shares Out
21,567,422
Trailing EPS
$-1.00
Book Value
$0.69
ROE
-95.1%
ROA
-47.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 456,021 | -19,154,988 | -20,642,994 | 16,089,573 | 890,568 | 15,200,547 | -5,850,255 |
| Dec 2024 | 615,873 | -8,693,526 | -8,706,145 | 15,370,511 | 1,425,463 | 13,946,129 | -4,863,776 |
| Dec 2023 | 731,493 | -9,218,890 | -9,212,417 | 1,050,793 | 276,039 | 774,754 | -6,997,375 |
| Dec 2022 | 8,939 | -1,991,582 | -1,998,055 | 1,003,287 | 389,257 | 614,030 | -1,346,518 |
TTM Snapshot
Revenues TTM
$315,227
NetIncome TTM
$-15,103,588
OpCashFlow TTM
—
Assets (Latest)
$14,172,795
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADVB | Advanced Biomed Inc. | $3.47M | $2.10 | — |
| ACON | Aclarion, Inc. | $3.95M | $1.37 | — |
| HLYK | HealthLynked Corp | $2.51M | $0.85 | — |
| BGLC | BioNexus Gene Lab Corp | $2.25M | $0.77 | — |
| BICX | BioCorRx Inc. | $6.22M | $0.21 | — |
News headlines (Yahoo Finance, 1h cache)
Mangoceuticals Partners with T7X to Become the First Nasdaq-Listed Company to Offer Tokenized Preferred Stock on the T7X Platform
2026-11-12 12:00 · Yahoo
Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
2026-08-13 20:05 · Yahoo
Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor
2026-07-30 14:35 · Yahoo
Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
2026-10-09 20:01 · Yahoo
Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
2026-08-05 20:05 · Yahoo
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
2026-08-04 20:05 · Yahoo
Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
2026-07-30 11:00 · Yahoo
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
2026-03-17 20:00 · Yahoo
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
2026-03-06 21:00 · Yahoo
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
2026-02-23 21:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.